VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells

Standard

VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. / Shein, Sergey A.; Kuznetsov, Ilya I.; Abakumova, Tatiana O.; Chelushkin, Pavel S.; Melnikov, Pavel A.; Korchagina, Anna A.; Bychkov, Dmitry A.; Seregina, Irina F.; Bolshov, Mikhail A.; Kabanov, Alexander V.; Chekhonin, Vladimir P.; Nukolova, Natalia V.

In: Molecular Pharmaceutics, Vol. 13, No. 11, 07.11.2016, p. 3712-3723.

Research output: Contribution to journal › Article › peer-review

Harvard

Shein, SA, Kuznetsov, II, Abakumova, TO, Chelushkin, PS, Melnikov, PA, Korchagina, AA, Bychkov, DA, Seregina, IF, Bolshov, MA, Kabanov, AV, Chekhonin, VP & Nukolova, NV 2016, 'VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells', Molecular Pharmaceutics, vol. 13, no. 11, pp. 3712-3723. https://doi.org/10.1021/acs.molpharmaceut.6b00519, https://doi.org/10.1021/acs.molpharmaceut.6b00519

APA

Shein, S. A., Kuznetsov, I. I., Abakumova, T. O., Chelushkin, P. S., Melnikov, P. A., Korchagina, A. A., Bychkov, D. A., Seregina, I. F., Bolshov, M. A., Kabanov, A. V., Chekhonin, V. P., & Nukolova, N. V. (2016). VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. Molecular Pharmaceutics, 13(11), 3712-3723. https://doi.org/10.1021/acs.molpharmaceut.6b00519, https://doi.org/10.1021/acs.molpharmaceut.6b00519

Vancouver

Shein SA, Kuznetsov II, Abakumova TO, Chelushkin PS, Melnikov PA, Korchagina AA et al. VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. Molecular Pharmaceutics. 2016 Nov 7;13(11):3712-3723. https://doi.org/10.1021/acs.molpharmaceut.6b00519, https://doi.org/10.1021/acs.molpharmaceut.6b00519

Author

Shein, Sergey A. ; Kuznetsov, Ilya I. ; Abakumova, Tatiana O. ; Chelushkin, Pavel S. ; Melnikov, Pavel A. ; Korchagina, Anna A. ; Bychkov, Dmitry A. ; Seregina, Irina F. ; Bolshov, Mikhail A. ; Kabanov, Alexander V. ; Chekhonin, Vladimir P. ; Nukolova, Natalia V. / VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. In: Molecular Pharmaceutics. 2016 ; Vol. 13, No. 11. pp. 3712-3723.

BibTeX

@article{e058d83d8d6245ce944f5d624c7afb5a,

title = "VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells",

abstract = "Targeted delivery of anticancer drugs to brain tumors, especially glioblastoma multiforme, which is the most frequent and aggressive type, is one of the important objectives in nanomedicine. Vascular endothelial growth factor (VEGF) and its receptor type II (VEGFR2) are promising targets because they are overexpressed by not only core tumor cells but also by migrated glioma cells, which are responsible for resistance and rapid progression of brain tumors. The purpose of the present study was to develop the liposomal drug delivery system combining enhanced loading capacity of cisplatin and high binding affinity to glioma cells. This was achieved by using of highly soluble cisplatin analogue, cis-diamminedinitratoplatinum(II), and antibodies against the native form of VEGF or VEGFR2 conjugated to liposome surface. The developed drug delivery system revealed sustained drug release profile, high affinity to antigens, and increased uptake by glioma C6 and U-87 MG cells. Pharmacokinetic study on glioma C6-bearing rats revealed prolonged blood circulation time of the liposomal formulation. The above features enabled the present drug delivery system to overcome both poor pharmacokinetics typical for platinum formulations and low loading capacity typical for conventional liposomal cisplatin formulations.",

keywords = "anti-VEGF and anti-VEGFR2 monoclonal antibody, cisplatin, glioma, PEGylated liposomes, targeted drug delivery",

author = "Shein, {Sergey A.} and Kuznetsov, {Ilya I.} and Abakumova, {Tatiana O.} and Chelushkin, {Pavel S.} and Melnikov, {Pavel A.} and Korchagina, {Anna A.} and Bychkov, {Dmitry A.} and Seregina, {Irina F.} and Bolshov, {Mikhail A.} and Kabanov, {Alexander V.} and Chekhonin, {Vladimir P.} and Nukolova, {Natalia V.}",

year = "2016",

month = nov,

day = "7",

doi = "10.1021/acs.molpharmaceut.6b00519",

language = "English",

volume = "13",

pages = "3712--3723",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

number = "11",

}

RIS

TY - JOUR

T1 - VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells

AU - Shein, Sergey A.

AU - Kuznetsov, Ilya I.

AU - Abakumova, Tatiana O.

AU - Chelushkin, Pavel S.

AU - Melnikov, Pavel A.

AU - Korchagina, Anna A.

AU - Bychkov, Dmitry A.

AU - Seregina, Irina F.

AU - Bolshov, Mikhail A.

AU - Kabanov, Alexander V.

AU - Chekhonin, Vladimir P.

AU - Nukolova, Natalia V.

PY - 2016/11/7

Y1 - 2016/11/7

N2 - Targeted delivery of anticancer drugs to brain tumors, especially glioblastoma multiforme, which is the most frequent and aggressive type, is one of the important objectives in nanomedicine. Vascular endothelial growth factor (VEGF) and its receptor type II (VEGFR2) are promising targets because they are overexpressed by not only core tumor cells but also by migrated glioma cells, which are responsible for resistance and rapid progression of brain tumors. The purpose of the present study was to develop the liposomal drug delivery system combining enhanced loading capacity of cisplatin and high binding affinity to glioma cells. This was achieved by using of highly soluble cisplatin analogue, cis-diamminedinitratoplatinum(II), and antibodies against the native form of VEGF or VEGFR2 conjugated to liposome surface. The developed drug delivery system revealed sustained drug release profile, high affinity to antigens, and increased uptake by glioma C6 and U-87 MG cells. Pharmacokinetic study on glioma C6-bearing rats revealed prolonged blood circulation time of the liposomal formulation. The above features enabled the present drug delivery system to overcome both poor pharmacokinetics typical for platinum formulations and low loading capacity typical for conventional liposomal cisplatin formulations.

AB - Targeted delivery of anticancer drugs to brain tumors, especially glioblastoma multiforme, which is the most frequent and aggressive type, is one of the important objectives in nanomedicine. Vascular endothelial growth factor (VEGF) and its receptor type II (VEGFR2) are promising targets because they are overexpressed by not only core tumor cells but also by migrated glioma cells, which are responsible for resistance and rapid progression of brain tumors. The purpose of the present study was to develop the liposomal drug delivery system combining enhanced loading capacity of cisplatin and high binding affinity to glioma cells. This was achieved by using of highly soluble cisplatin analogue, cis-diamminedinitratoplatinum(II), and antibodies against the native form of VEGF or VEGFR2 conjugated to liposome surface. The developed drug delivery system revealed sustained drug release profile, high affinity to antigens, and increased uptake by glioma C6 and U-87 MG cells. Pharmacokinetic study on glioma C6-bearing rats revealed prolonged blood circulation time of the liposomal formulation. The above features enabled the present drug delivery system to overcome both poor pharmacokinetics typical for platinum formulations and low loading capacity typical for conventional liposomal cisplatin formulations.

KW - anti-VEGF and anti-VEGFR2 monoclonal antibody

KW - cisplatin

KW - glioma

KW - PEGylated liposomes

KW - targeted drug delivery

UR - http://www.scopus.com/inward/record.url?scp=84994496390&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.6b00519

DO - 10.1021/acs.molpharmaceut.6b00519

M3 - Article

C2 - 27654150

VL - 13

SP - 3712

EP - 3723

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -

ID: 7606884